Ajanta Pharma Limited Overview
Ajanta Pharma is a Mumbai-headquartered, promoter-controlled specialty pharmaceutical formulation company whose economic engine is branded generics sold through its own field forces in India, Asia and Francophone/Anglophone Africa, complemented by a fast-scaling US generics business and a residual African institutional (antimalarial tender) franchise. It is distinctive among Indian mid-caps for three reasons: a portfolio built around first-to-market and niche molecules in cardiology, ophthalmology, dermatology and pain; very high gross margins (78.3% in FY2026) achieved through fully integrated, captive manufacturing at seven Indian plants; and a capital-light, cash-returning posture — negligible debt, a 33% return on capital employed in FY2026, and regular dividends and tender-offer buybacks. FY2026 was a milestone year in which revenue crossed INR 5,000 crore for the first time (INR 5,453 crore, +17%), driven by a 49% surge in US generics. The investment debate now centres on sustainability of US growth, Asia volatility and premium valuation.
Company's own description
In its FY2026 results communication, Ajanta describes itself as a specialty pharmaceutical formulation company with a major focus on branded generic business across India, Asia and Africa, complemented by a generics business in the United States and an institution business in Africa, with manufacturing facilities located in India. Management's stated growth model (Managing Director Yogesh Agrawal, Business Standard, December 2025) rests on new product launches, market-share gains in existing products, expansion into new countries and therapies, expense optimisation and digitalisation — a framework restated in the Q1 FY2027 results release.
Independent characterisation
Ajanta is best understood as a portfolio of four distinct businesses sharing one manufacturing and R&D platform:
-
India branded generics (≈30% of FY2026 revenue). A specialty-led domestic franchise in which cardiology alone contributed 36% of India branded revenue in FY2026 (Q4 FY2026 call). Ajanta's operating model is to be first or early to launch novel combinations and new molecules in under-penetrated specialty niches, which historically gave it leadership positions in ophthalmology and dermatology sub-categories. Per IQVIA MAT March 2026, India branded performance exceeded Indian Pharmaceutical Market (IPM) growth by 33% (company press release, 5 May 2026). The India line also includes a small trade generics business (INR 188 crore in FY2026 vs INR 179 crore in FY2025).
-
Emerging-market branded generics — Asia and Africa (≈37% combined). Ajanta operates its own sales teams in roughly 30 countries across South-East Asia (notably the Philippines), South Asia, the Middle East, Central Asia and Francophone/Anglophone Africa. Management restricts itself to 8–12 focus markets in each region rather than spreading thinly (Business Standard, December 2025). PL Capital estimates the branded generics business carries roughly a 30% operating margin.
-
US generics (≈29%). A portfolio of oral solid generics manufactured at USFDA-inspected Indian sites, sold through Ajanta Pharma USA Inc. The business is deliberately niche: management states that nearly 40% of its US portfolio holds a 30% or higher market share (Business Standard, December 2025). Revenue grew 49% in FY2026 to INR 1,557 crore and 57% in Q1 FY2027 (to INR 487 crore; USD 51 million).
-
Africa institution (≈3%). Tender-based supply of antimalarials and other products to global health procurement agencies; Ajanta was the first generic company worldwide to obtain WHO Geneva prequalification for an anti-malarial (company history). This business has shrunk structurally and is now a swing contributor (INR 160 crore in FY2026).
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model mix | ~100% product sales (finished dosage formulations). No material service, subscription or licensing income identified. In-licensing (Biocon semaglutide) adds a distribution/commercialisation model from late 2026/2027 |
| Branded vs generic mix | Branded generics ~66–70% of revenue (66% in Q1 FY2027; ~71% per ICICI Direct FY2026); US generics ~29–30%; institutional ~3% |
| Value chain position | Integrated: R&D (formulation development, bioequivalence, regulatory filings) → captive manufacturing (7 Indian plants; limited API for captive use) → own-field-force marketing in branded markets → wholesale/channel distribution in the US |
| Customer types | Prescribing physicians (specialists: cardiologists, ophthalmologists, dermatologists, physicians) influence demand; paying customers are distributors, stockists, pharmacies; in the US, wholesalers, retail pharmacy chains and group purchasing organisations; in Africa institution, donor-funded procurement agencies |
| End-markets | Indian domestic pharmaceutical market; emerging-market branded generics (Asia, Middle East, Central Asia, Africa); US generic prescription drugs; donor-funded antimalarial procurement |
Strategy
Stated strategy themes (FY2026 annual report / investor communications)
Management's strategy is consistently framed around (i) new product launches, especially first-to-market products in specialty therapies; (ii) market-share gains in existing brands; (iii) expansion into new countries and therapies (recent entries into nephrology and gynaecology in India; new countries in Asia/Africa); (iv) expense optimisation; and (v) digitalisation across operations. The FY2026 Annual Report reiterates principles of quality without compromise, growth with margin discipline and value creation with integrity.
Strategic initiatives — last 24 months
| Date | Initiative | Detail / target |
|---|---|---|
| Mar 2025 | Pithampur liquid formulation facility | Capacity addition to meet emerging-market demand; existing capacity at 175% utilisation |
| FY2025–FY2026 | Field-force expansion | Two years of sales-team expansion in India (200 MRs added in specialty segments; 12 launches cited by PL Capital); productivity now improving |
| FY2025–FY2026 | Geographic expansion in Asia/Africa | Board-level decision to enhance presence across select Asian and African geographies |
| Dec 2025 | Inorganic growth war chest | INR 1,000 crore+ earmarked for brand/portfolio acquisitions (pain, dermatology, nephrology, gynaecology), not manufacturing assets |
| Dec 2025 | Semaglutide in-licensing (Biocon) | 26 countries; launch late 2026/early 2027 |
| Jan 2026 | Ajanta Pharma Ireland Ltd | New wholly owned subsidiary |
| FY2026–FY2027 | Semaglutide filings outside India | Filing programme commencing (ICICI Direct) |
| 2023–ongoing | ESG data platform | Credible Innovations partnership for AI-based ESG accounting and reporting |
| Ongoing | Capital return | Dividend payouts (76% PAT payout in FY2025); periodic tender-offer buybacks |
Management guidance
| Item | Guidance | Date / source |
|---|---|---|
| FY2027 revenue growth | High-teen growth (16–18%) | Q4 FY2026 call, May 2026 |
| FY2027 EBITDA margin | ~27% (range 26–28%) | Q4 FY2026 call; maintained in July 2026 |
| Rest-of-FY2027 growth (post Q1) | Mid-single to upper-mid-single digit growth for the remaining quarters, citing US price erosion, new competition and a thin launch pipeline | Q1 FY2027 call as reported by Equirus, July 2026 |
| Asia | Recovery; high double-digit growth expected over time; Q1 deferred sales to be recognised in Q2 | Q4 FY2026 / Q1 FY2027 calls |
| Africa branded | High double-digit growth | Q4 FY2026 call |
| US launches | None in Q2 FY2027; most approvals expected in Q4 FY2027 | Q1 FY2027 call |
Products & Services
Disclosure limitation: Ajanta does not publish a brand-level revenue catalog in its results materials, and brand-by-brand sales are sourced in India from proprietary IQVIA data. The catalog below therefore lists therapy franchises and disclosed launches; individual brand revenue, pricing and launch years are not publicly disclosed unless stated.
India branded generics
| Franchise | Description & positioning | Target prescriber | Disclosed facts |
|---|---|---|---|
| Cardiology (cardio-metabolic) | Largest India franchise; anti-hypertensives, lipid-lowering, anti-platelet and fixed-dose combinations; focus on new combinations | Cardiologists, consulting physicians | 36% of India branded revenue in FY2026 (Q4 FY2026 call). Growth in the cardiac division has at times trailed IPM growth (Tickertape summary of FY2026 commentary). Company was directed by Indian regulator's expert committee to revise the bioequivalence protocol for a cilnidipine + metoprolol fixed-dose combination (Medical Dialogues, 2026) — evidence of continued cardiac FDC development |
| Ophthalmology | Specialty eye-care portfolio (anti-allergics, anti-infectives, anti-glaucoma, dry-eye) where Ajanta holds leadership positions in several sub-segments | Ophthalmologists | Leadership described in company history; brand-level data not publicly disclosed |
| Dermatology | Topicals and orals in acne, fungal infections, pigmentation and dermatitis | Dermatologists | Identified by management as an area for bolt-on acquisitions (December 2025) |
| Pain management | Analgesics, musculoskeletal and anti-inflammatory products | Orthopaedics, physicians | Identified as an M&A gap-filling area (December 2025) |
| Nephrology (new) | Recent entry | Nephrologists | Entered recently; management sees "meaningful scope" (Business Standard, December 2025) |
| Gynaecology (new) | Recent entry | Gynaecologists | Entered recently (December 2025) |
| Trade generics | Unbranded/low-promotion generics sold through trade channels | Pharmacies / trade | INR 188 crore in FY2026 vs INR 179 crore in FY2025; INR 49 crore in Q4 of both years |
Launch cadence: 26 new products launched in India in FY2026, including five first-time-in-India launches (ICICI Direct, Q4 FY2026); eight new products launched in Q1 FY2027 (Equirus).
Asia branded generics
Portfolio spans cardiology, anti-diabetics, antibiotics, gastro, dermatology, ophthalmology and pain, increasingly tilted to chronic therapies. A consensus narrative cites ~25 new chronic-therapy launches planned to support FY2026+ growth (Simply Wall St analyst narrative, December 2024). Key markets include the Philippines (own subsidiary), Sri Lanka, Myanmar, Cambodia, Middle East (GCC) and Central Asia (exact market list not disclosed in the sources reviewed). FY2026 revenue: INR 1,175 crore (–1%), hurt by logistics and geopolitical disruptions (Q4 FY2026 call).
Africa branded generics
Strong presence in Francophone West and Central Africa and selected East African markets; portfolio emphasises anti-infectives, antimalarials (branded), cardio-metabolic and pain, with liquid oral formulations important (driver of the Pithampur liquids expansion). Eight new products introduced in FY2026 (one in Q4). FY2026 revenue: INR 861 crore (+15%); Q4 FY2026 +37%; Q1 FY2027 +~29%.
US generics
| Item | Detail |
|---|---|
| Portfolio type | Oral solids (tablets, capsules, extended-release); niche, limited-competition molecules |
| Named products | Topiramate Extended-Release Capsules (final USFDA approval, 2023); individual product revenues not disclosed |
| Pipeline | 19 ANDAs awaiting USFDA approval at end-FY2026 (press release, 5 May 2026) |
| Market share profile | ~40% of portfolio holds ≥30% market share (management, December 2025) |
| Revenue | INR 1,557 crore FY2026 (+49%); USD 51 million in Q1 FY2027 (+30% in USD terms) |
| Near-term launch outlook | No new US launches expected in Q2 FY2027; most potential approvals pushed to Q4 FY2027 (Equirus, July 2026) |
Africa institution
Antimalarial artemisinin-combination therapies supplied under donor-funded tenders (Global Fund-type procurement). Revenue INR 160 crore in FY2026 (+9%); Q4 FY2026 +71% on improved second-half order flow.
In-licensed: semaglutide (GLP-1 receptor agonist)
| Item | Detail |
|---|---|
| Counterparty | Biocon Ltd (manufacturer and supplier) |
| Signed | Announced 24 December 2025 |
| Territory | 26 countries in Africa, the Middle East and Central Asia: exclusive in 23, semi-exclusive in 3 |
| Indication | Glycaemic control in adults with type 2 diabetes |
| Patent context | Product patent expires in most territories in March 2026 |
| Expected launch | After approvals anticipated late 2026 to early 2027 |
| Sell-side estimate | PL Capital estimates ~INR 200 crore of FY2028E sales at healthy margins (estimate, not company guidance) |
| Further filings | Company to begin filing semaglutide outside India (ICICI Direct, Q4 FY2026 note) |
Financial Narrative
Income statement (consolidated)
Sources: StockAnalysis (consolidated, INR millions converted to crore) for revenue, gross profit, operating income, net income, DPS, finance cost; Ajanta press release/Directors' Report FY2026 for revenue, PAT and EBITDA (FY2026 EBITDA INR 1,395 crore, +11% YoY; FY2025 EBITDA derived from the 11% growth figure); Craytheon for PBT; Motilal Oswal/askfuzz for EPS. Discrepancy note: Craytheon reports FY2025 gross profit of INR 3,577 crore vs StockAnalysis INR 3,505 crore (different cost-of-goods classification).
Margins and growth
Revenue CAGR FY2022–FY2026 (derived): ~13.0%. PAT CAGR FY2022–FY2026 (derived): ~10.3%. Company states a 3-year revenue and PAT CAGR of ~14% (FY2023–FY2026).
Commentary. The five-year record has three phases. FY2022–FY2023 saw margin compression: gross margin fell ~320 bps to 70.3% and EBIT margin dropped to 18.2% in FY2023 as input-cost inflation, freight disruption and the decline of the institutional business bit, driving the only PAT decline in the series (–17.5%). FY2024 was the inflection year: gross margin recovered to 73.4%, EBIT margin rebuilt to 24.8% and PAT rose 38.8% on price, mix and cost normalisation. FY2025–FY2026 have been about scaling: gross margin expanded a further ~490 bps to 78.3%, powered by branded mix and high-share US products, but the gain was reinvested in field-force expansion (employee cost +21.8% YoY in Q4 FY2026) and other expenses (+42.8% YoY in Q4 FY2026), so EBITDA margin actually slipped to ~26% in FY2026 from ~27% in FY2025. FY2026 operating leverage was therefore weaker than the headline 17% revenue growth suggests; PAT grew 14.7%, also helped by lower finance cost.
Quarterly trajectory FY2026–Q1 FY2027
Notes: Q2 and Q3 FY2026 revenue and Q2 FY2026 PAT are derived (Q3 revenue from Q4's reported +3.4% QoQ; Q2 as the residual of FY2026; Q2 PAT from 9M FY2026 PAT of INR 789 crore). Q1 FY2027 EBITDA is adjusted, excluding forex loss (company), equivalent to a ~28% margin; gross margin was 80% (+100 bps QoQ). Q3 FY2026 EBITDA margin was 27.8% (IIFL).
Balance sheet
Sources: Craytheon (FY2026 total assets, net worth, current ratio, D/E 0.06, debt +448.7% YoY). FY2025 debt derived from the reported 448.7% increase. Short/long-term debt split and net debt are not publicly disclosed in the sources reviewed. The FY2026 debt increase most plausibly reflects short-term working-capital borrowing or lease liabilities — not confirmed.
Cash flow and shareholder returns
Sources: 5paisa citing company (FY2024 dividends INR 642 crore); Craytheon (FY2025/FY2026 dividends paid; FY2026 FCF INR 164 crore); FY2025 Directors' Report (buyback INR 285 crore paid to shareholders + INR 65 crore tax, executed in Q1 FY2025). FY2025 payout: management cited a 76% PAT payout in FY2025 (Quartr summary).
Return and efficiency ratios
ROA (derived, FY2026): ~17.2% (PAT / year-end total assets). ROIC, net debt/EBITDA and the cash conversion cycle are not publicly disclosed in the sources reviewed; net debt/EBITDA is almost certainly negative (net cash). Craytheon reports interest coverage of 75.8x for FY2026 on a different definition.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (INR Cr) | FY2025 | FY2026 |
|---|---|---|
India branded generics (incl. trade generics) | 1,452 | 1,654 |
Asia branded generics | 1,191 | 1,175 |
Africa branded generics | 750 | 861 |
Sub-total branded generics | 3,393 | 3,690 |
US generics | 1,047 | 1,557 |
Africa institution | 147 | 160 |
Other operating revenue (derived residual) | 61 | 46 |
Total revenue from operations | 4,648 | 5,453 |
Business line — YoY growth (%)
| Business line — YoY growth (%) | FY2025 | FY2026 |
|---|---|---|
India branded generics | — | 14 |
Asia branded generics | — | -1 |
Africa branded generics | — | 15 |
US generics | — | 49 |
Africa institution | — | 9 |
Total revenue | 10 | 17 |
Business line — % of total revenue (derived)
| Business line — % of total revenue (derived) | FY2025 | FY2026 |
|---|---|---|
India branded generics | 31.2 | 30.3 |
Asia branded generics | 25.6 | 21.5 |
Africa branded generics | 16.1 | 15.8 |
US generics | 22.5 | 28.6 |
Africa institution | 3.2 | 2.9 |
Business Lines (Quarterly)
| Business line (INR Cr) | Q4 FY2025 | Q4 FY2026 | Q4 growth % | Q1 FY2027 | Q1 growth % |
|---|---|---|---|---|---|
India branded | 369 | 404 | 9 | ~510 | 24 |
Asia branded | 303 | 274 | -10 | ~260 | -16 |
Africa branded | 133 | 182 | 37 | not separately verified | ~29 |
Total branded generics | 805 | 859 | 7 | 1,059 | 13 |
US generics | 325 | 505 | 56 | 487 | 57 |
Africa institution | 28 | 48 | 71 | not separately verified | — |
Group Entities
| Entity | Jurisdiction | Function |
|---|---|---|
Ajanta Pharma Limited | India | Parent; R&D, manufacturing, India and export sales |
Ajanta Pharma USA Inc. | United States | US generics marketing and distribution |
Ajanta Pharma Philippines Inc. | Philippines | Branded generics marketing in the Philippines |
Ajanta Pharma (Mauritius) Ltd | Mauritius | Holding / export hub; historically associated with a WHO-GMP manufacturing site |
Ajanta Pharma Ireland Ltd | Ireland | Incorporated January 2026; purpose not publicly detailed (likely European regulatory/market-access vehicle — analyst inference) |
Other overseas marketing subsidiaries | Various (Asia/Africa) | Not individually verified in sources reviewed |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 |
Total income incl. other income (INR Cr) | 3,457 | 3,841 | 4,293 | 4,743 | 5,625 |
Gross profit (INR Cr) | 2,457 | 2,632 | 3,088 | 3,505 | 4,269 |
Operating income / EBIT (INR Cr) | 808 | 680 | 1,046 | 1,129 | 1,325 |
EBITDA company-reported (INR Cr) | — | — | — | 1,257 | 1,395 |
Profit before tax (INR Cr) | — | — | — | 1,189 | 1,378 |
Net income / PAT (INR Cr) | 713 | 588 | 816 | 920 | 1,056 |
EPS basic (INR) | — | — | — | 73.56 | 84.53 |
Dividend per share bonus-adjusted (INR) | 6.33 | 7 | 36 | 28 | 28 |
Finance cost (INR Cr) | 10.2 | 5.8 | 7.2 | 20.7 | 16.1 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth | 15.6 | 12.0 | 12.4 | 10.4 | 17.3 |
Gross margin | 73.5 | 70.3 | 73.4 | 75.4 | 78.3 |
Operating (EBIT) margin | 24.2 | 18.2 | 24.8 | 24.3 | 24.3 |
EBITDA margin company-reported | — | — | — | 27.0 | 25.6 |
Net margin | 21.3 | 15.7 | 19.4 | 19.8 | 19.4 |
Net income growth | 9.0 | -17.5 | 38.8 | 12.8 | 14.7 |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 1,303 | 1,353 | 1,375 | 1,422 | 1,626 |
PAT (INR Cr) | 255 | 260 | 274 | 267 | 334 |
EBITDA (INR Cr) | — | — | — | 333 | 454 |
EPS basic (INR) | 20.44 | — | — | 21.35 | 26.75 |
Balance Sheet and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
Total assets (INR Cr) | — | 6,155 |
Shareholders' equity / net worth (INR Cr) | — | 4,527 |
Total debt (INR Cr, derived from D/E 0.06) | ~50 | ~272 |
Current ratio (x) | — | 2.64 |
Dividends & Capital Returns
| Metric (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Dividends paid | 642 | 349 | 350 |
Buyback outlay incl. buyback tax | — | 350 | 0 |
Free cash flow | — | — | 164 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | — | 23.3 |
Return on net worth company-reported (%) | — | — | — | — | 25 |
ROCE company-reported (%) | — | — | — | — | 33 |
Interest coverage EBIT/finance cost (x, derived) | 79 | 117 | 145 | 55 | 82 |
Debt/equity (x) | — | — | — | — | 0.06 |
Asset turnover revenue/total assets (x, derived) | — | — | — | — | 0.89 |
Revenue by Region
| Region (INR Cr) | FY2025 | FY2026 |
|---|---|---|
India | 1,452 | 1,654 |
Asia ex-India | 1,191 | 1,175 |
Africa (branded + institution) | 897 | 1,021 |
United States | 1,047 | 1,557 |
Region growth (%)
| Region growth (%) | FY2026 |
|---|---|
India | 13.9 |
Asia ex-India | -1.3 |
Africa (branded + institution) | 13.8 |
United States | 48.7 |
Valuation Snapshot
| Metric | Value | As-of / source |
|---|---|---|
Latest price | INR 3,399.40 | 12 Oct 2026 (IIFL) |
52-week range | INR 2,329.90 – 3,796.95 | Aug 2026 (Anand Rathi / IIFL) |
6-month return | ~+18.8% | Sep 2026 (Anand Rathi) |
1-year return | ~+35% to +38% | Sep 2026 (Kotak Neo / Anand Rathi) |
3-year return | ~+105% to +110% | Aug–Sep 2026 (Anand Rathi) |
5-year return | ~+139.5% | as of 2 Apr 2026 (Equentis) — not refreshed |
Beta | ~0.7 | Equentis |
Valuation Multiples
| Multiple | Ajanta | Basis |
|---|---|---|
P/E (trailing) | 37.4x | TTM EPS ~INR 90.84 (FY2026 84.53 + Q1 FY2027 26.75 – Q1 FY2026 20.44) |
P/E (FY2026) | 40.2x | FY2026 EPS 84.53 |
P/B | ~9.4x | FY2026 net worth INR 4,527 crore |
EV/Sales (FY2026) | ~7.8x | Market-cap basis; net cash not deducted |
EV/EBITDA (FY2026) | ~30x | Market-cap basis; FY2026 EBITDA INR 1,395 crore |
Dividend yield | ~0.8–0.9% | INR 28 FY2026 / INR 32 FY2027 interim |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (INR) |
|---|---|---|---|
ICICI Securities | 31 Jul 2026 | Hold (downgrade) | 3,260 |
Equirus Securities | 31 Jul 2026 | Reduce | — |
Motilal Oswal | Jul 2026 | Buy (reported) | 4,000 (reported) |
PL Capital | Dec 2025 | Buy | 3,200 |
Consensus (Trendlyne) | Aug 2026 | Buy | ~3,761 |
“—” = not publicly disclosed.
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share bonus-adjusted (INR) | 6.33 | 7 | 36 | 28 | 28 |
Dividends paid (INR Cr) | — | — | 642 | 349 | 350 |
Analyst Conclusions
Guidance and expectations
Management guided in May 2026 to high-teen (16–18%) revenue growth and ~27% EBITDA margin for FY2027, then struck a more cautious tone in July 2026, guiding to mid- to upper-mid-single-digit growth for the remainder of the year. Sell-side expectations reported in press imply low- to mid-teens EPS growth into FY2028 (ICICI Securities values the stock at 28x FY2028E EPS).
Bull case
-
Margin engine intact: gross margin at 80% in Q1 FY2027 and ROCE of 33% indicate a franchise that can absorb investment and still compound earnings in the mid-teens.
-
Multiple growth options: semaglutide in 26 EMs (~INR 200 crore FY2028E per PL Capital), Africa high double-digit growth, Asia recovery from a depressed base, and INR 1,000 crore of firepower for India brand acquisitions.
-
Regulatory de-risking: Paithan VAI removes the main overhang on the US franchise; 19 pending ANDAs support US growth from Q4 FY2027.
Bear case
-
US normalisation: management itself flags price erosion, new competition and no Q2 launches; after +49% and +57% growth, a reversal in a 29%-of-revenue business would hit earnings disproportionately.
-
Weak operating leverage and cash conversion: EBITDA margin fell to ~26% in FY2026 despite +17% revenue; FCF of INR 164 crore in FY2026 is low relative to INR 1,056 crore PAT.
-
Valuation and supply overhang: ~37x trailing earnings and ~9.4x book, alongside promoter selling (2.76% in June 2026) and rising pledges, limit upside; two brokers rate the stock Hold/Reduce.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q2 FY2027 results: Asia catch-up of deferred Q1 sales; US sequential trend | Late Oct / early Nov 2026 |
| Semaglutide approvals and first launches in licensed territories | Late 2026 – early 2027 |
| First acquisition under INR 1,000 crore programme | FY2027 (unconfirmed) |
| US ANDA approvals (most pushed to Q4 FY2027) | Jan–Mar 2027 |
| Commissioning of Pithampur liquid facility | — |
| Reconciliation of FY2027 growth guidance | Q2/Q3 FY2027 calls |
| Further promoter sales or pledge changes | Ongoing |
| Next USFDA inspections (Dahej / other sites) | Unscheduled |
| FY2027 dividend / potential buyback | Q3–Q4 FY2027 / May 2027 |
Analyst verdict
Ajanta Pharma enters the second half of FY2027 as one of the highest-quality mid-cap franchises in Indian pharmaceuticals, but one whose share price already discounts much of that quality. The fundamental record is genuinely strong: revenue has compounded at ~13% over FY2022–FY2026 to INR 5,453 crore, gross margin has expanded by roughly 800 bps since FY2023 to 78%, ROCE stands at 33%, the balance sheet is essentially ungeared, and the July 2026 quarter delivered 25% revenue growth and 31% PAT growth with an 80% gross margin. The Paithan VAI outcome and the Biocon semaglutide licence materially improve the medium-term risk-reward, and the INR 1,000 crore acquisition allocation gives management a lever to accelerate the India business, which is already outgrowing the market by a third.
Against this, three issues temper conviction. First, the growth mix has become more dependent on the US, the most cyclical and deflationary of Ajanta's markets; management's own July commentary — mid-single-digit growth for the rest of the year and no near-term launches — signals that FY2026–Q1 FY2027 US growth was a peak, not a run-rate. Second, operating leverage and cash conversion in FY2026 were weaker than headline growth implied, as field-force and other expenses outpaced revenue and working capital absorbed cash. Third, the stock trades at ~37x trailing earnings and ~9.4x book while promoters have been net sellers and pledges have risen.
Net, Ajanta is a hold-quality compounder at current levels: the business merits a premium multiple, but upside from here depends on evidence that Asia recovers in Q2, that semaglutide launches on schedule, and that capital is deployed in value-accretive acquisitions. Investors should treat the Q2 FY2027 print as the key arbiter of whether FY2027 full-year growth tracks the May "high-teens" guidance or the July caution.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Board tenure / key dates | Background (as disclosed) |
|---|---|---|---|---|
Mannalal B. Agrawal | Chairman | Non-Executive, Non-Independent (promoter) | Long-standing (~46 years per Simply Wall St) | Co-founder; also director of Ajanta Pharma Philippines and Ajanta Pharma (Mauritius) |
Madhusudan B. Agrawal | Executive Vice-Chairman | Executive (promoter) | Re-appointed for 5 years from 1 April 2025 | Co-founder; director of Ajanta Pharma USA Inc. |
Yogesh M. Agrawal | Managing Director | Executive (promoter) | Director since 29 April 2000; current term from 1 April 2023; born 14 January 1972 (age 54) | MBA; leads the global business |
Rajesh M. Agrawal | Joint Managing Director | Executive (promoter) | Director since 30 April 2013; current term from 1 May 2023; born 31 March 1976 (age 50) | Leads operations/strategy; publicly articulated M&A plans (December 2025) |
David Rasquinha | Lead Independent Director | Independent | — | — |
Medha Joshi | Independent Director | Independent | — | Not detailed in sources reviewed |
Simi Thapar | Independent Director | Independent | Appointed at the 2024 AGM | Not detailed in sources reviewed |
Rajesh Shashikant Dalal | Independent Director | Independent | — | Not detailed in sources reviewed |
Executive Leadership Team
| Name | Title |
|---|---|
Yogesh M. Agrawal | Managing Director |
Rajesh M. Agrawal | Joint Managing Director |
Arvind Agrawal | Chief Financial Officer |
Gaurang Shah | Senior Vice President – Legal & Company Secretary |
Directors' Remuneration
| Executive | Total remuneration | Source / year |
|---|---|---|
Yogesh M. Agrawal (MD) | INR 24.64 crore (INR 246.4 million); salary ~57.7% of total | Simply Wall St, FY2025 basis |
Madhusudan B. Agrawal (Executive Vice-Chairman) | INR 4.84 crore | Simply Wall St, FY2025 basis |
Mannalal B. Agrawal (Chairman) | INR 0.075 crore (sitting fees/commission) | Simply Wall St |
Stock-based pay | Share-Based Incentive Plan 2019 (SBIP 2019): 25,325 options vested/issued in FY2025; 13,000 US-employee options converted to cash-settled SARs | FY2025 Directors' Report |
Board & Management Changes
| Date | Change |
|---|---|
2024 AGM | Induction of new independent directors including Simi Thapar; board committees reconstituted following retirement of earlier independent directors |
1 April 2025 | Madhusudan B. Agrawal re-appointed Executive Director & Vice-Chairman (5 years) — approved at AGM on 17 July 2025 |
FY2026 | David Rasquinha continues as Lead Independent Director; a director retiring by rotation recommended for re-appointment at the 47th AGM (16 July 2026) |
Shareholding Pattern
| Category | Mar 2026 (%) | Post 9 June 2026 / Jun 2026 (%) |
|---|---|---|
Promoters & promoter group | 66.25 | 63.49 |
Mutual funds | 15.22 | — |
Foreign portfolio investors | 8.26 | ~7.7 |
Other domestic institutions | 3.14 | ~3.7 |
Retail & others | 7.12 | ~7.0 |
Major Shareholders
| Holder | Stake (%) | Type | Date |
|---|---|---|---|
Rajesh Agrawal Trust (Rajesh M. Agrawal, trustee) | 14.47 | Promoter | Mar 2026 |
Aayush Agrawal Trust | 11.30 | Promoter | Jun 2026 |
Ravi Agrawal Trust | 10.24 | Promoter | Jun 2026 (from 13.00%) |
Gabs Investments Pvt Ltd | 10.08 | Promoter | Jun 2026 |
UTI Flexi Cap Fund | 3.19 | Mutual fund | Mar 2026 |
Kotak Mahindra Mutual Fund (block purchase) | ≥1.68 | Mutual fund | Jun 2026 (21.02 lakh shares bought) |
Canara Robeco Mutual Fund (various schemes) | ~1.5 (largest single scheme) | Mutual fund | Dec 2025 |
Aditya Birla Sun Life Mutual Fund (block purchase) | ≥1.08 | Mutual fund | Jun 2026 (13.47 lakh shares bought) |
Competitive Landscape
Competitors by Segment
| Business line | Principal competitors |
|---|---|
India branded — cardiology/cardio-metabolic | Sun Pharma, Torrent Pharma, Lupin, Mankind Pharma, Eris Lifesciences, Micro Labs, Alkem |
India branded — ophthalmology | Sun Pharma (ophthalmic division), FDC Ltd, Entod Pharmaceuticals, Cipla, Alcon/Novartis (innovator) |
India branded — dermatology | Glenmark, Sun Pharma, Mankind, Alkem, Abbott India |
India branded — pain | Alkem, Ipca Laboratories, Mankind, Abbott India |
Asia branded generics | Unilab (Philippines, local leader), Getz Pharma, Hetero, Sun Pharma, Torrent, Dr. Reddy's, multinationals |
Africa branded generics | Ipca Laboratories, Cipla, Strides Pharma, Bliss GVS Pharma, Sanofi, Aspen, local manufacturers |
US generics | Zydus Lifesciences, Lupin, Alembic Pharma, Aurobindo, Torrent, Unichem, Glenmark, Teva |
Africa institution (antimalarials) | Ipca Laboratories, Macleods, Strides, Guilin Pharma, Novartis (innovator) |
Key Competitors
| Company | FY2026 revenue (INR Cr) | Notes |
|---|---|---|
Ajanta Pharma | 5,453 | Revenue growth 17%; gross margin 78%; EBITDA margin 26%; R&D ~5% of revenue |
Ipca Laboratories | 9,646 | Closest overlap in Africa institution, pain and EM branded generics |
Alembic Pharmaceuticals | 7,345 | Overlap in US generics and India specialty |
Sun Pharmaceutical Industries | 58,462 | Category leader in India specialty and EMs (Craytheon also reports INR 60,434 crore — source discrepancy) |



